<DOC>
	<DOCNO>NCT00940420</DOCNO>
	<brief_summary>This 2 arm open-label study assess safety tolerability combination treatment Peginterferon alfa ( Pegasys ) Ribavirin ( Copegus ) patient chronic hepatitis C. Patients assign receive Peginterferon alfa ( Pegasys ) 180 mcg sc week Ribavirin ( Copegus ) 800 - 1200 mg po daily either 24 48 week . Allocation treatment arm discretion investigator ( mainly accord genotype ) . Adverse event monitor throughout study hematologic parameter every 2 week twice 24-week follow-up .</brief_summary>
	<brief_title>A Study Combination Treatment With Pegasys ( Peginterferon Alfa ) Copegus ( Ribavirin ) Patients With Chronic Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>adult patient &gt; /= 18 year age serologic evidence chronic hepatitis C infection compensate liver disease negative pregnancy test male female use 2 form contraception study 6 month treatment history evidence medical condition associate chronic liver disease HCV hepatitis A , hepatitis B HIV infection hepatocellular carcinoma severe concomitant disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>